Zhang, Bing
Ma, Sai
Rachmin, Inbal
He, Megan
Baral, Pankaj
Choi, Sekyu
Gonçalves, William A.
Shwartz, Yulia
Fast, Eva M.
Su, Yiqun
Zon, Leonard I.
Regev, Aviv
Buenrostro, Jason D.
Cunha, Thiago M.
Chiu, Isaac M.
Fisher, David E.
Hsu, Ya-Chieh
Article History
Received: 22 May 2019
Accepted: 13 December 2019
First Online: 22 January 2020
Competing interests
: L.I.Z. is a founder and stockholder of Fate Therapeutics, Scholar Rock and CAMP4 Therapeutics. D.E.F. has a financial interest in Soltego, a company developing salt-inducible kinase inhibitors for topical skin-darkening treatments that might be used for a broad set of human applications. The interests of D.E.F. were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. A.R. is a member of the Scientific Advisory Board (SAB) of Thermo Fisher Scientific, Neogene Therapeutics, Asimov and Syros Pharmaceuticals; an equity holder of Immunitas; and a founder and an equity holder of Celsius Therapeutics. I.M.C. is an SAB member of GSK Pharmaceuticals and Kintai Therapeutics. A provisional patent application has been filed based on this work (applicants: President and Fellows of Harvard College and The General Hospital Corporation; inventors: Y.-C.H., B.Z., D.E.F. and I.R.; application number: 62/903,517; status: pending/provisional; aspect covered: methods and compositions for controlling hair greying). All of the other authors declare no competing interests.